Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Stable solid forms of enclomiphene and enclomiphene citrate

Inactive Publication Date: 2017-12-07
F I S FAB ILTALIANA SINTETICI SPA
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

As a further aspect, the problem is that of providing an improved solid form of Enclomiphene base with higher flowability, thus suitable for the industrial manufacturing form Enclomiphene citrate using said Enclomiphene base as a chemical synthetic intermediate and / or for the industrial manufacturing pharmaceutical products comprising said Enclomiphene.
Moreover, another problem to be solved is the provision of a better solid form of Enclomiphene base, suspension of the which filters more quickly, thus, consequently, providing Enclomiphene (base) and then Enclomiphene citrate or Enclomiphene citrate having needle shaped crystal habit, all three of them with higher chemical purity, especially for the content of Cis-Clomiphene impurity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Stable solid forms of enclomiphene and enclomiphene citrate
  • Stable solid forms of enclomiphene and enclomiphene citrate
  • Stable solid forms of enclomiphene and enclomiphene citrate

Examples

Experimental program
Comparison scheme
Effect test

example 1

on of Clomiphene Citrate from 1-{4-[2-(Diethylamino)ethoxy]phenyl}-1,2-diphenylethanol

[0282]

[0283]Step 1

[0284]A round bottomed flask fitted with distillation equipment was loaded with 250 g of 1-{4-[2-(Diethylamino)ethoxy]phenyl}-1,2-diphenylethanol and 1250 mL of toluene. To this mixture, 85 mL of HCl 32% w / w were added, the temperature was raised to the boiling point and all the water was azeotropically removed by means of a Dean-Stark apparatus, obtaining 2-{4-[(E / Z)-1,2-diphenylethenyl]phenoxy}-N,N-diethylethanamine hydrochloride, as mixture of geometric isomers of formula (V-Z) and (V-E).

[0285]Step 2

[0286]The reaction mixture was brought to 60° C. and, maintaining this temperature, 500 mL of acetic acid were added during 30′. The water content was checked below 500 ppm (Karl Fischer titration).

[0287]A warm solution (50-60° C.), prepared with 60 g of dichloro dimethyl hydantoin (1,3-dichloro-5,5-dimethyl hydantoin; abbreviated DCDMI) (0.474 mol. equiv.) in 600 mL of toluene, was...

example 2a

n of Salt of Trans-Clomiphene with Racemic Binaphthyl-Phosphoric Acid, Starting from Clomiphene Citrate

[0290]

[0291]A round bottom flask was charged 100 gr of Clomiphene Citrate (HPLC analysis (A / A %): 65.21% E-Clomiphene, 34.06% Z-Clomiphene) and 1000 mL of Methanol. The suspension was stirred at 30° C. up the complete dissolution. Then a solution of racemic binaphthyl-phosphoric acid (abbreviated BPA) 30 gr (0.515 eq) in 30 mL of DMF was added. At the end of addition the mixture was stirred for 1 h at 30° C. The obtained suspension was filtered and the solid was washed with 100 mL of Methanol.

[0292]50.4 gr of E-Clomiphene BPA salt were obtained.

[0293]HPLC Analysis (A / A %): 97.04% E-Chlomiphene, 2.5% Z-Clomiphene.

example 2b

n of Salt of Trans-Clomiphene with Racemic Binaphthyl-Phosphoric Acid, Starting from Clomiphene Citrate

[0294]A round bottom flask was charged 50 gr of Clomiphene Citrate (the same as that used in example 2a) and 500 mL of Methanol. The suspension was heated at 40-45° C. and stirred up to the complete dissolution. Then a solution of BPA 15 gr (0.515 eq) in 300 mL of methanol was added. At the end of addition the mixture was stirred for 1 h at 20° C. The obtained suspension was filtered and the solid was washed with 100 mL of Methanol.

[0295]24.1 gr of E-Clomiphene BPA salt were obtained.

[0296]HPLC Analysis (A / A %): 98.96% E-Chlomiphene, 0.69% Z-Clomiphene.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention refers to new solid forms of Enclomiphene citrate and Enclomiphene base, processes for preparing thereof and uses.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is continuation of U.S. patent application Ser. No. 15 / 115,133, filed Jul. 28, 2016, which is a 371 of PCT / EP2015 / 074746 filed Oct. 26, 2015, which claims the benefit of European Patent Application No. 14190738.6, filed Oct. 28, 2014, each of which is incorporated herein by reference.TECHNICAL FIELD[0002]The present invention refers to processes for the preparation the active pharmaceutical ingredient named Clomiphene and, in particular, trans-Clomiphene, i.e. Enclomiphene.[0003]Moreover, the invention refers to new solid forms of trans-Clomiphene and trans-Clomiphene citrate and processes for preparing thereof.BACKGROUND ART[0004]Clomiphene is an active pharmaceutical ingredient used as ovulatory stimulant to treat ovulatory dysfunction and polycystic ovary syndrome.[0005]Clomiphene has chemical name Ethanamine, 2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethyl and it is a mixture of the geometric isomers trans-Clo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07C217/54C07C51/41C07C59/265C07C53/10C07C217/18C07C213/08
CPCC07C217/54C07C213/08C07C53/10C07B2200/13C07C217/18C07C51/412C07C59/265A61P15/00
Inventor PADOVAN, PIERLUIGICARUANA, LORENZOTESSON, NICOLAS
Owner F I S FAB ILTALIANA SINTETICI SPA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com